POLO trial for advanced pancreatic cancer: a | EurekAlert!
A trial of olaparib for pancreatic cancer that has spread (POLO) | Cancer Research UK
ASCO GI 2021: Results From the Phase 3 POLO Trial
ASCO GI 2021: Results From the Phase 3 POLO Trial
Maintenance Olaparib vs Placebo in Germline BRCA-Mutated Metastatic Pancreatic Cancer - The ASCO Post
HCP's Thoughts On Pancreatic Cancer | Knowledge | CREATION.co
Cancer Trial Results
Trial results PARP inhibitors in pancreatic cancer | Download Scientific Diagram
POLO trial is back | OS is negative | But the manuscript is full SPIN CYCLE | Insane! - YouTube
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Olaparib for Pancreatic Cancer with BRCA Mutations - NCI
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
ASCO GI 2021: Results From the Phase 3 POLO Trial
New Homologous Recombination Deficiency Findings in Pancreatic Cancer Alter Treatment Focus
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
NCCN Guidelines Updates: Pancreatic Cancer in: Journal of the National Comprehensive Cancer Network Volume 17 Issue 5.5 (2019)
Phase III POLO Trial - Slideset Download - Clin Onc June 2019 | CCO
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Cancer Trial Results
Sotorasib in KRAS p.G12C-mutated Pancreatic Cancer
Olaparib in Metastatic Pancreatic Cancer
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
